

Jason A Efstathiou

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7658008/jason-a-efstathiou-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

166
papers

5,678
citations

34
h-index

72
g-index

182
ext. papers

7,616
ext. citations

5.5
avg, IF

5.8
L-index

| # | Paper | IF | Citations |
|-----|---|------|-----------|
| 166 | HIV and Hodgkin Lymphoma Survival: A Prospective Study in Botswana.. <i>JCO Global Oncology</i> , 2022 , 8, e2100163 | 3.7 | 0 |
| 165 | Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis.. <i>Lancet Oncology</i> , 2022 , | 21.7 | 8 |
| 164 | What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.. <i>European Urology</i> , 2022 , | 10.2 | 2 |
| 163 | Association of Race With Receipt of Proton Beam Therapy for Patients With Newly Diagnosed Cancer in the US, 2004-2018.. <i>JAMA Network Open</i> , 2022 , 5, e228970 | 10.4 | 1 |
| 162 | High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium.. <i>European Urology</i> , 2022 , | 10.2 | 1 |
| 161 | Assessment of Proton Beam Therapy Use Among Patients With Newly Diagnosed Cancer in the US, 2004-2018.. <i>JAMA Network Open</i> , 2022 , 5, e229025 | 10.4 | 2 |
| 160 | Association of the USPSTF Grade D Recommendation Against Prostate-Specific Antigen Screening With Prostate Cancer-Specific Mortality.. <i>JAMA Network Open</i> , 2022 , 5, e2211869 | 10.4 | 2 |
| 159 | The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2021 , 81, 95-95 | 10.2 | 12 |
| 158 | Accuracy of Pathologic Diagnosis in Patients With Lymphoma and Survival: A Prospective Analysis From Botswana. <i>JCO Global Oncology</i> , 2021 , 7, 1620-1632 | 3.7 | |
| 157 | Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , 7, 544-552 | 13.4 | 17 |
| 156 | Current State of Personalized Genitourinary Cancer Radiotherapy in the Era of Precision Medicine. <i>Frontiers in Oncology</i> , 2021 , 11, 675311 | 5.3 | 3 |
| 155 | F-Fluciclovine PET/CT performance in biochemical recurrence of prostate cancer: a systematic review. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 997-1006 | 6.2 | 5 |
| 154 | Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy. <i>European Urology Oncology</i> , 2021 , | 6.7 | 1 |
| 153 | EA8185: Phase 2 study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node positive urothelial carcinoma (INSPIRE) An ECOG-ACRIN and NRG Collaboration.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS4590-TPS4590 | 2.2 | |
| 152 | Contemporary and Emerging Approaches to Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2021 , 35, 567-584 | 3.1 | 2 |
| 151 | Complications and Outcomes of Salvage Cystectomy after Trimodality Therapy. <i>Journal of Urology</i> , 2021 , 206, 29-36 | 2.5 | 1 |
| 150 | Management of Muscle-Invasive Bladder Cancer During a Pandemic: Impact of Treatment Delay on Survival Outcomes for Patients Treated With Definitive Concurrent Chemoradiotherapy. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 41-46.e1 | 3.3 | 2 |

| | | | |
|-----|--|------|-----|
| 149 | NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 109, 174-185 | 4 | 31 |
| 148 | Setting the stage for bladder preservation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 209-212 | 2.8 | 2 |
| 147 | Impact of Community-Based Clinical Breast Examinations in Botswana. <i>JCO Global Oncology</i> , 2021 , 7, 17-26 | 3.7 | 1 |
| 146 | INTACT (S/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: Safety update on first 73 patients.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 428-428 | 2.2 | 4 |
| 145 | The impact of a positive family history on clinical and pathologic outcomes of active surveillance for prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 225-225 | 2.2 | 1 |
| 144 | Differences in Quality of Life Between Men and Women who Undergo Bladder Preservation with Trimodality Therapy. <i>Bladder Cancer</i> , 2021 , 7, 279-284 | 1 | |
| 143 | Trimodality Therapy With or Without Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 362-368 | 3.3 | 3 |
| 142 | Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , | 4 | 4 |
| 141 | The Program for Enhanced Training in Cancer: An Initial Experience of Supporting Capacity Building for Oncology Training in Sub-Saharan Africa. <i>JCO Global Oncology</i> , 2020 , 6, 13-13 | 3.7 | 1 |
| 140 | Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. <i>JAMA Oncology</i> , 2020 , 6, 735-743 | 13.4 | 23 |
| 139 | Association of the Placement of a Perirectal Hydrogel Spacer With the Clinical Outcomes of Men Receiving Radiotherapy for Prostate Cancer: A Systematic Review and Meta-analysis. <i>JAMA Network Open</i> , 2020 , 3, e208221 | 10.4 | 18 |
| 138 | Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. <i>European Urology Oncology</i> , 2020 , 3, 420-423 | 6.7 | 11 |
| 137 | Transcriptome profiling of NRG Oncology/RTOG 9601: Validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 276-276 | 2.2 | 5 |
| 136 | INTACT: Phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer SWOG/NRG1806.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS586-TPS586 | 2.2 | 2 |
| 135 | Radiotherapy use in the treatment of gastrointestinal cancers in Medicare patients: An analysis of a CMS database.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 800-800 | 2.2 | |
| 134 | Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 329-354 | 7.3 | 159 |
| 133 | An analysis of trends in prostate cancer treatment from a CMS database.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e19288-e19288 | 2.2 | |
| 132 | Resolution of a High Grade and Metastatic BK Polyomavirus-Associated Urothelial Cell Carcinoma Following Radical Allograft Nephroureterectomy and Immune Checkpoint Treatment: A Case Report. <i>Transplantation Proceedings</i> , 2020 , 52, 2720-2725 | 1.1 | 3 |

| | | | |
|-----|--|------|-----|
| 131 | Quality Indicators for Bladder Cancer Services: A Collaborative Review. <i>European Urology</i> , 2020 , 78, 43-52 | 10.2 | 13 |
| 130 | Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. <i>European Urology</i> , 2020 , 77, 38-52 | 10.2 | 258 |
| 129 | SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2019 , 37, 61-83 | 4 | 31 |
| 128 | Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer. <i>European Urology</i> , 2019 , 76, 59-68 | 10.2 | 63 |
| 127 | The current state of randomized clinical trial evidence for prostate brachytherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 599-610 | 2.8 | 6 |
| 126 | MicroRNA Biomarkers for Patients With Muscle-Invasive Bladder Cancer Undergoing Selective Bladder-Sparing Trimodality Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 104, 197-206 | 4 | 10 |
| 125 | Editorial comment. <i>Urology</i> , 2019 , 124, 189-190 | 1.6 | |
| 124 | Proton versus photon-based radiation therapy for prostate cancer: emerging evidence and considerations in the era of value-based cancer care. <i>Prostate Cancer and Prostatic Diseases</i> , 2019 , 22, 509-521 | 6.2 | 13 |
| 123 | Molecular Characterization of Neuroendocrine-like Bladder Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 3908-3920 | 12.9 | 42 |
| 122 | Combining Immunotherapy with Radiotherapy for the Treatment of Genitourinary Malignancies. <i>European Urology Oncology</i> , 2019 , 2, 79-87 | 6.7 | 17 |
| 121 | Association Between Declared Hurricane Disasters and Survival of Patients With Lung Cancer Undergoing Radiation Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 322, 269-277 | 7.4 | 16 |
| 120 | Trends in the use of proton beam therapy among newly diagnosed cancer patients in the United States.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 6551-6551 | 2.2 | |
| 119 | Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 941-948 | 7.3 | |
| 118 | Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years. <i>Journal of Urology</i> , 2019 , 201, 721-727 | 2.5 | 9 |
| 117 | Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline. <i>Journal of Urology</i> , 2019 , 201, 528-534 | 2.5 | 31 |
| 116 | 328. Kaposi Sarcoma in High Population ART Utilization Setting: An Observational Study in Botswana. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S174-S175 | 1 | 78 |
| 115 | POETIC (Program for Enhanced Training in Cancer): An Initial Experience of Supporting Capacity Building for Oncology Training in Sub-Saharan Africa. <i>Oncologist</i> , 2019 , 24, 1557-1561 | 5.7 | 7 |
| 114 | EDITORIAL COMMENT. <i>Urology</i> , 2019 , 133, 171-172 | 1.6 | |

| | | | |
|-----|---|------|-----|
| 113 | Proton therapy for prostate cancer: A review of the rationale, evidence, and current state. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 628-636 | 2.8 | 11 |
| 112 | Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder Cancer. <i>JAMA Surgery</i> , 2019 , 154, 184-185 | 5.4 | 1 |
| 111 | Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 23-31.e3 | 3.3 | 21 |
| 110 | PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53. <i>Oncogene</i> , 2018 , 37, 2793-2805 | 9.2 | 32 |
| 109 | Definitive Radiation Therapy and Survival in Clinically Node-Positive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 101, 1188-1193 | 4 | 12 |
| 108 | Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. <i>JAMA Oncology</i> , 2018 , 4, e175230 | 13.4 | 49 |
| 107 | Clinical needs assessment for sexual health among cancer patients receiving pelvic radiation: Implications for development of a radiation oncology sexual health clinic. <i>Practical Radiation Oncology</i> , 2018 , 8, 206-212 | 2.8 | 2 |
| 106 | Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 213-218 | 3.3 | 10 |
| 105 | An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer. <i>Cancer Discovery</i> , 2018 , 8, 288-303 | 24.4 | 76 |
| 104 | The prognostic effect of salvage surgery and radiotherapy in patients with recurrent primary urethral carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 10.e7-10.e14 | 2.8 | 9 |
| 103 | Routine bladder cancer treatment dictates divergence from trial-derived regimens: Results of treatment at 44 radiotherapy centers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 9.e19-9.e25 | 2.8 | 1 |
| 102 | Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2018 , 199, 407-415 | 2.5 | 23 |
| 101 | Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy. <i>Cancer Treatment Reviews</i> , 2018 , 70, 88-97 | 14.4 | 14 |
| 100 | Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). <i>European Urology</i> , 2018 , 74, 294-306 | 10.2 | 176 |
| 99 | Clinical characteristics and outcomes of nonurothelial cell carcinoma of the bladder: Results from the National Cancer Data Base. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 78.e1-78.e12 | 2.8 | 23 |
| 98 | Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. <i>European Urology</i> , 2018 , 74, 99-106 | 10.2 | 18 |
| 97 | Long-term impact of a faculty mentoring program in academic medicine. <i>PLoS ONE</i> , 2018 , 13, e0207634 | 3.7 | 23 |
| 96 | Comparing Adjuvant vs Early-Salvage Radiotherapy After Radical Prostatectomy-Reply. <i>JAMA Oncology</i> , 2018 , 4, 1620-1621 | 13.4 | |

| | | | |
|----|--|------|-----|
| 95 | Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer. <i>Lancet Oncology, The</i> , 2018 , 19, e683-e695 | 21.7 | 44 |
| 94 | Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline. <i>Practical Radiation Oncology</i> , 2018 , 8, 354-360 | 2.8 | 90 |
| 93 | Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. <i>Journal of Urology</i> , 2018 , | 2.5 | 11 |
| 92 | Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 102, 287-295 | 4 | 38 |
| 91 | What is the best way to radiate the prostate in 2016?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 59-68 | 2.8 | 28 |
| 90 | Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 563-569.e3 | 3.3 | 7 |
| 89 | Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. <i>European Urology</i> , 2017 , 71, 952-960 | 10.2 | 153 |
| 88 | Long-term results of adjuvant versus early salvage postprostatectomy radiation: A large single-institutional experience. <i>Practical Radiation Oncology</i> , 2017 , 7, e125-e133 | 2.8 | 14 |
| 87 | Long-term quality of life after definitive treatment for prostate cancer: patient-reported outcomes in the second posttreatment decade. <i>Cancer Medicine</i> , 2017 , 6, 1827-1836 | 4.8 | 22 |
| 86 | Hydrogel rectum-prostate spacers mitigate the uncertainties in proton relative biological effectiveness associated with anterior-oblique beams. <i>Acta Oncologica</i> , 2017 , 56, 575-581 | 3.2 | 11 |
| 85 | Characterization of efficacy and toxicity after high-dose pelvic reirradiation with palliative intent for genitourinary second malignant neoplasms or local recurrences after full-dose radiation therapy in the pelvis: A high-volume cancer center experience. <i>Advances in Radiation Oncology</i> , 2017 , 2, 140-147 | 3.3 | 6 |
| 84 | Multicriteria plan optimization in the hands of physicians: a pilot study in prostate cancer and brain tumors. <i>Radiation Oncology</i> , 2017 , 12, 168 | 4.2 | 16 |
| 83 | Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long-term Results of a Single-institution Experience. <i>Clinical Genitourinary Cancer</i> , 2017 , | 3.3 | 4 |
| 82 | Reply to Saeid Safiri and Erfan Ayubi Letter to the Editor re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. <i>Eur Urol</i> 2017;71:952-60. Methodological issues to | 10.2 | 1 |
| 81 | Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer. <i>European Urology</i> , 2017 , 71, 729-737 | 10.2 | 81 |
| 80 | The Rationale for Post-Operative Radiation in Localized Bladder Cancer. <i>Bladder Cancer</i> , 2017 , 3, 19-30 | 1 | 16 |
| 79 | The impact of MRE11 in nuclear to cytoplasmic ratio on outcomes in muscle invasive bladder cancer an analysis of NRG/RTOG 8802, 8903, 9506, 9706, 9906, and 0233.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 343-343 | 2.2 | 5 |
| 78 | The prognostic utility of hemoglobin and lymphocytopenia in bladder-sparing therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 370-370 | 2.2 | |

| | | | |
|----|---|------|-----|
| 77 | Prostate cancer specific mortality and overall survival outcomes for salvage radiation therapy after radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9-9 | 2.2 | |
| 76 | Prostate cancer specific mortality and overall survival outcomes for salvage radiation therapy after radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2017 , 2017, 9-9 | 2.2 | |
| 75 | Subtyping muscle-invasive bladder cancer to assess clinical response to trimodality therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 287-287 | 2.2 | |
| 74 | Outcomes and tolerability of selective bladder preservation by combined modality therapy for invasive bladder cancer in elderly patients.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 316-316 | 2.2 | 1 |
| 73 | HIV Infection and Survival Among Women With Cervical Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3749-3757 | 2.2 | 87 |
| 72 | Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: A secondary analysis of RTOG 94-08 and 96-01. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 430.e1-7 | 2.8 | 8 |
| 71 | Painting Dose: The ART of Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, 722-728 | 4 | 4 |
| 70 | Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3648-3654 | 2.2 | 200 |
| 69 | Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016 , 2, 165-202 ¹ | | 22 |
| 68 | Bladder cancer. <i>Lancet, The</i> , 2016 , 388, 2796-2810 | 40 | 669 |
| 67 | Disruption of SLX4-MUS81 Function Increases the Relative Biological Effectiveness of Proton Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 95, 78-85 | 4 | 23 |
| 66 | National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. <i>Cancer</i> , 2016 , 122, 1505-12 | 6.4 | 19 |
| 65 | Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma. <i>World Journal of Urology</i> , 2016 , 34, 97-103 | 4 | 37 |
| 64 | Establishing and Delivering Quality Radiation Therapy in Resource-Constrained Settings: The Story of Botswana. <i>Journal of Clinical Oncology</i> , 2016 , 34, 27-35 | 2.2 | 32 |
| 63 | Global Radiation Oncology From the Trainee Perspective: A View From Beyond the Bunker. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 94, 438-9 | 4 | 4 |
| 62 | Can We Advance Proton Therapy for Prostate? Considering Alternative Beam Angles and Relative Biological Effectiveness Variations When Comparing Against Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 95, 454-464 | 4 | 34 |
| 61 | Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1054-5 | 27.4 | |
| 60 | Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08. <i>European Urology</i> , 2016 , 69, 204-10 | 10.2 | 26 |

| | | | |
|----|---|------|----|
| 59 | Patient reported outcomes in NRG Oncology/RTOG 0938, evaluating two ultrahypofractionated regimens (UHR) for prostate cancer (CaP).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 27-27 | 2.2 | 1 |
| 58 | Exploring multidisciplinary practice patterns in the management of muscle invasive bladder cancer (MIBC) across the U.S. and Canada in 2015.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 368-368 | 2.2 | 1 |
| 57 | Early salvage versus adjuvant post-prostatectomy radiation therapy: Long-term results of a large institutional experience.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 99-99 | 2.2 | 2 |
| 56 | Quantitative study of prostate cancer using three dimensional fiber tractography. <i>World Journal of Radiology</i> , 2016 , 8, 397-402 | 2.9 | 5 |
| 55 | Long-term outcomes after bladder-preserving combined-modality therapy for patients with muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 398-398 | 2.2 | |
| 54 | Renal function in bladder cancer patients after trimodality therapy: Long-term results of a large institutional experience.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 453-453 | 2.2 | |
| 53 | Re-irradiation of the pelvis for a genitourinary second malignant neoplasm or a local recurrence after full-dose pelvic radiotherapy for a pelvic cancer: Experience in a high-volume cancer center.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 494-494 | 2.2 | |
| 52 | Development and validation of contouring guidelines for post-cystectomy adjuvant radiation of bladder cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 409-409 | 2.2 | |
| 51 | Risk factors for disease progression after post-prostatectomy salvage radiation: Long-term results of a large institutional experience.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 110-110 | 2.2 | |
| 50 | Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider?. <i>Translational Andrology and Urology</i> , 2016 , 5, 702-710 | 2.3 | 11 |
| 49 | Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank. <i>Bladder Cancer</i> , 2016 , 2, 203-213 | 1 | 2 |
| 48 | Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. <i>BJU International</i> , 2016 , 118, 279-85 | 5.6 | 9 |
| 47 | Predictors of Timely Access of Oncology Services and Advanced-Stage Cancer in an HIV-Endemic Setting. <i>Oncologist</i> , 2016 , 21, 731-8 | 5.7 | 22 |
| 46 | NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 1213-1224 | 7.3 | 73 |
| 45 | The Natural History and Outcome Predictors of Metastatic Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2016 , 2, 480-487 | 5.1 | 9 |
| 44 | Management and outcomes of clinical stage IIA/B seminoma: Results from the National Cancer Data Base 1998-2012. <i>Practical Radiation Oncology</i> , 2016 , 6, e249-e258 | 2.8 | 10 |
| 43 | Words of Wisdom. Re: Radical Cystectomy vs. Chemoradiation in T2-4aN0M0 Bladder Cancer: A Case-control Study. <i>European Urology</i> , 2016 , 69, 757-8 | 10.2 | |
| 42 | Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, 78-86 | 4 | 31 |

| | | | |
|----|--|------|-----|
| 41 | Beyond a moonshot: insurance coverage for proton therapy. <i>Lancet Oncology, The</i> , 2016 , 17, 559-61 | 21.7 | 19 |
| 40 | Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, 1028-1036 | 4 | 82 |
| 39 | Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, 1046-1053 | 4 | 34 |
| 38 | Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer. <i>Cancer</i> , 2016 , 122, 78-83 | 6.4 | 29 |
| 37 | Words of wisdom. Re: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. <i>European Urology</i> , 2015 , 67, 975 | 10.2 | 4 |
| 36 | Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkers. <i>Molecular Cancer Research</i> , 2015 , 13, 713-20 | 6.6 | 25 |
| 35 | Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer. <i>Journal of the National Cancer Institute</i> , 2015 , 107, | 9.7 | 67 |
| 34 | Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 53-64 | 2.8 | 11 |
| 33 | National trends in the recommendation of radiotherapy after prostatectomy for prostate cancer before and after the reporting of a survival benefit in March 2009. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, e167-72 | 3.3 | 10 |
| 32 | Declining Use of Radiotherapy for Adverse Features After Radical Prostatectomy: Results From the National Cancer Data Base. <i>European Urology</i> , 2015 , 68, 768-74 | 10.2 | 82 |
| 31 | Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. <i>Nature Reviews Urology</i> , 2015 , 12, 225-35 | 5.5 | 101 |
| 30 | Lung cancer cell line screen links fanconi anemia/BRCA pathway defects to increased relative biological effectiveness of proton radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 91, 1081-9 | 4 | 62 |
| 29 | Treatment Trends for Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 1976-7 | 27.4 | |
| 28 | Cost implications and complications of overtreatment of low-risk prostate cancer in the United States. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 61-8 | 7.3 | 49 |
| 27 | Immunotherapy and Radiation - A New Combined Treatment Approach for Bladder Cancer?. <i>Bladder Cancer</i> , 2015 , 1, 15-27 | 1 | 16 |
| 26 | Cervical Cancer in Botswana: Current State and Future Steps for Screening and Treatment Programs. <i>Frontiers in Oncology</i> , 2015 , 5, 239 | 5.3 | 28 |
| 25 | DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity. <i>Seminars in Radiation Oncology</i> , 2015 , 25, 237-50 | 5.5 | 48 |
| 24 | Response. <i>Journal of the National Cancer Institute</i> , 2015 , 107, | 9.7 | 1 |

| | | | |
|----|---|------|-----|
| 23 | Bladder preservation strategies. <i>Hematology/Oncology Clinics of North America</i> , 2015 , 29, 289-300, ix | 3.1 | 8 |
| 22 | Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. <i>European Urology</i> , 2014 , 66, 120-37 | 10.2 | 190 |
| 21 | Weight gain on androgen deprivation therapy: which patients are at highest risk?. <i>Urology</i> , 2014 , 83, 1316-21 | 6.21 | 14 |
| 20 | Outcomes in a multi-institutional cohort of patients treated with intraoperative radiation therapy for advanced or recurrent renal cell carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 88, 618-23 | 4 | 25 |
| 19 | Addressing the growing cancer burden in the wake of the AIDS epidemic in Botswana: The BOTSOGO collaborative partnership. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 89, 468-75 | 4 | 25 |
| 18 | Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3801-9 | 2.2 | 245 |
| 17 | EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation. <i>Cancer Research</i> , 2014 , 74, 2825-34 | 10.1 | 50 |
| 16 | Cervical brachytherapy exchange: steps toward oncology capacity building in Botswana. <i>Oncologist</i> , 2014 , 19, e1-2 | 5.7 | 10 |
| 15 | Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 88, 1048-56 | 4 | 57 |
| 14 | Words of wisdom. Re: Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. <i>European Urology</i> , 2013 , 63, 181-2 | 10.2 | 4 |
| 13 | Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry. <i>Journal of Oncology Practice</i> , 2013 , 9, e90-5 | 3.1 | 22 |
| 12 | Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. <i>European Urology</i> , 2012 , 61, 705-11 | 10.2 | 264 |
| 11 | Postoperative radiation for prostate cancer. <i>Lancet, The</i> , 2012 , 380, 1974-6 | 40 | 7 |
| 10 | Developing a national radiation oncology registry: From acorns to oaks. <i>Practical Radiation Oncology</i> , 2012 , 2, 10-7 | 2.8 | 30 |
| 9 | Adjuvant radiation therapy for early stage seminoma: proton versus photon planning comparison and modeling of second cancer risk. <i>Radiotherapy and Oncology</i> , 2012 , 103, 12-7 | 5.3 | 25 |
| 8 | TU-G-BRB-04: Optimal Frequency of CT Imaging for Monitoring Target Volume and Estimating Delivered Dose in Standard and Hypofractionated Prostate Proton Therapy. <i>Medical Physics</i> , 2011 , 38, 3779-3779 | 4.4 | |
| 7 | Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4055-61 | 2.2 | 146 |
| 6 | Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. <i>Journal of Clinical Oncology</i> , 2009 , 27, 92-9 | 2.2 | 201 |

| | | | |
|---|--|------|-----|
| 5 | Life, liberty, and the pursuit of protons: an evidence-based review of the role of particle therapy in the treatment of prostate cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2009 , 15, 312-8 | 2.2 | 24 |
| 4 | Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. <i>European Urology</i> , 2008 , 54, 816-23 | 10.2 | 148 |
| 3 | Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 71, 1302-8 | 4 | 18 |
| 2 | Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31. <i>Cancer</i> , 2007 , 110, 2691-9 | 6.4 | 77 |
| 1 | Bladder-sparing approaches to invasive disease. <i>World Journal of Urology</i> , 2006 , 24, 517-29 | 4 | 17 |